Fig. 5

GLPG1790 triggers myogenic differentiation and counteracts ERMS stem-like phenotype. a Cell lysates from RD and TE671 cells untreated (DMSO) (−) or treated (+) with GLPG1790 for indicated times were analysed by immunoblotting with specific antibodies for indicated proteins; α-Tubulin expression shows the loading of samples. Representative of three independent experiments. b Immunofluorescence experiments showing the expression of MYOD1 and MyHC, at 72 h after GLPG1790 treatment. Images captured under ApoTome microscope at 40× magnification. c Representative microphotographs of RD and TE671 cells in adherent conditions (Adherent) and in stem cell (SC) medium after 15 days of incubation in the absence (SC-DMSO) or in the presence of 3.5 μM GLPG1790 (SC-GLPG1790). d Histograms of percentage of CD133 positive cells determined by FACS analysis. Results represent the mean values ± SD of four independent experiments. Statistical significance: **p < 0.01, ***p < 0.001 vs. Adherent, ^$$$ p < 0.001 vs. SC-DMSO. e Histograms of percentage of CXCR4 positive cells determined by FACS analysis. Results represent the mean value of four independent experiments ± SD. Statistical significance: **p < 0.01, ***p < 0.001 vs. Adherent, ^$$ p < 0.01 vs. SC-DMSO. f Western blot analysis of Nanog in protein lysates from RD and TE671 cells in adherent, SC-DMSO or SC-GLPG1790 cultured conditions for 15 days; α-Tubulin expression shows equal loading of samples. Representative of three independent experiments